Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
03-Oct-2025 | 5,519 | 5,519 | 5,425 | 5,442 | 17,112 | 60,43,34,335 | 74,421 |
06-Oct-2025 | 5,495.5 | 5,507 | 5,369.5 | 5,494 | 20,515 | 57,89,13,703 | 58,294 |
07-Oct-2025 | 5,536.5 | 5,536.5 | 5,455 | 5,492 | 18,433 | 56,81,31,734 | 65,156 |
08-Oct-2025 | 5,503.5 | 5,544.5 | 5,465 | 5,493.5 | 25,166 | 96,65,68,134.5 | 1,24,593 |
09-Oct-2025 | 5,520 | 5,560.5 | 5,471 | 5,480.5 | 22,869 | 59,80,11,332.5 | 74,591 |
10-Oct-2025 | 5,480.5 | 5,500 | 5,412.5 | 5,454.5 | 27,658 | 93,56,84,374 | 1,21,872 |
13-Oct-2025 | 5,458.5 | 5,510 | 5,436.5 | 5,492.5 | 14,277 | 42,86,44,982.5 | 46,945 |
14-Oct-2025 | 5,545 | 5,545 | 5,454 | 5,493 | 20,122 | 43,35,76,589 | 45,349 |
15-Oct-2025 | 5,519.5 | 5,606.5 | 5,498.5 | 5,566.5 | 17,421 | 95,83,82,600 | 1,36,176 |
16-Oct-2025 | 5,566 | 5,589.5 | 5,500 | 5,524 | 12,412 | 93,52,25,018.5 | 1,42,771 |
17-Oct-2025 | 5,533 | 5,590 | 5,513 | 5,581.5 | 12,066 | 36,16,30,786.5 | 44,624 |
20-Oct-2025 | 5,592.5 | 5,648 | 5,538 | 5,557 | 18,615 | 56,96,95,360.5 | 57,045 |
21-Oct-2025 | 5,557 | 5,585.5 | 5,508.5 | 5,547.5 | 3,606 | 9,37,22,872 | 3,380 |
23-Oct-2025 | 5,575.5 | 5,599 | 5,519.5 | 5,534 | 11,216 | 27,50,55,755.5 | 29,127 |
24-Oct-2025 | 5,569 | 5,569 | 5,489.5 | 5,545 | 12,441 | 65,01,66,260 | 82,801 |
27-Oct-2025 | 5,560 | 5,580 | 5,440.5 | 5,475.5 | 12,460 | 39,36,87,858.5 | 46,031 |
28-Oct-2025 | 5,466 | 5,468 | 5,321 | 5,432 | 18,821 | 84,46,37,909.5 | 78,347 |
29-Oct-2025 | 5,432 | 5,545 | 5,415.5 | 5,535 | 19,238 | 69,24,46,877.5 | 88,592 |
30-Oct-2025 | 5,540 | 5,540.5 | 5,454 | 5,525 | 11,161 | 43,48,56,935 | 44,082 |
31-Oct-2025 | 5,525 | 5,531 | 5,477 | 5,506.5 | 15,951 | 98,27,96,913 | 1,39,406 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
